Current monitoring and treatment of progressive fibrosing interstitial lung disease: a survey of physicians in Japan, the United States, and the European Union

References

• Raghu G. Interstitial lung disease. Goldman’s Cecil Medicine. 25th ed. Philadelphia: Saunders; 2016. p. 575–588.
   Google Scholar
• Valeyre D, Duchemann B, Nunes H. Interstitial lung diseases. In: Annesi-Maesano I, Lundbäck B, Viegi G, editors. Respiratory epidemiology. Sheffield: European Respiratory Society; 2014. p. 79–87.
   Google Scholar
• Olson AL, Gifford AH, Inase N, et al. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype. Eur Respir Rev. 2018;27(150):180077.
   PubMed Web of Science ®Google Scholar
• Antoine M, Mlika M. Interstitial lung disease. StatPearls. Treasure Island (FL). 2020; [cited 2020 Dec 9]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31082128.
   Google Scholar
• Duchemann B, Annesi-Maesano I, Jacobe de Naurois C, et al. Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris. Eur Respir J. 2017;50(2):1602419.
   PubMed Web of Science ®Google Scholar
• Coultas DB, Zumwalt RE, Black WC, et al. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994;150(4):967–972.
   PubMed Web of Science ®Google Scholar
• Demedts M, Wells AU, Anto JM, et al. Interstitial lung diseases: an epidemiological overview. Eur Respir J Suppl. 2001;32:2s–16s.
   PubMedGoogle Scholar
• Karakatsani A, Papakosta D, Rapti A, et al. Epidemiology of interstitial lung diseases in Greece. Respir Med. 2009;103(8):1122–1129.
   PubMed Web of Science ®Google Scholar
• Musellim B, Okumus G, Uzaslan E, et al. Epidemiology and distribution of interstitial lung diseases in Turkey. Clin Respir J. 2014;8(1):55–62.
   PubMed Web of Science ®Google Scholar
• Mapel DW, Hunt WC, Utton R, et al. Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts. Thorax. 1998;53(6):469–476.
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Sverzellati N, Devaraj A, et al. Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax. 2014;69(3):216–222.
   PubMed Web of Science ®Google Scholar
• Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–748.
   PubMed Web of Science ®Google Scholar
• Akira M, Inoue Y, Arai T, et al. Long-term follow-up high-resolution CT findings in non-specific interstitial pneumonia. Thorax. 2011;66(1):61–65.
   PubMed Web of Science ®Google Scholar
• Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35(6):1322–1328.
   PubMed Web of Science ®Google Scholar
• De Sadeleer LJ, Verleden SE, Vos R, et al. Advances in lung transplantation for interstitial lung diseases. Curr Opin Pulm Med. 2020;26(5):518–525.
   PubMed Web of Science ®Google Scholar
• Hosenpud JD, Bennett LE, Keck BM, et al. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet. 1998;351(9095):24–27.
   PubMed Web of Science ®Google Scholar
• Thabut G, Mal H, Castier Y, et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg. 2003;126(2):469–475.
   PubMed Web of Science ®Google Scholar
• Kolb M, Vasakova M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019;20(1):57.
   PubMedGoogle Scholar
• Cottin V, Wollin L, Fischer A, et al. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev. 2019;28(151):180100.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res. 2017;4(1):e000212.
   PubMed Web of Science ®Google Scholar
• Wells AU, Brown KK, Flaherty KR, et al. Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: What’s in a name? Eur Respir J. 2019;53(2):1801939.
   PubMedGoogle Scholar
• Brown KK, Martinez FJ, Walsh SLF, et al. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020;55(6):2000085.
   PubMed Web of Science ®Google Scholar
• Hodnett PA, Naidich DP. Fibrosing interstitial lung disease. A practical high-resolution computed tomography-based approach to diagnosis and management and a review of the literature. Am J Respir Crit Care Med. 2013;188(2):141–149.
   PubMed Web of Science ®Google Scholar
• Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. 2020;383(10):958–968.
   PubMed Web of Science ®Google Scholar
• Cosgrove GP, Bianchi P, Danese S, et al. Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey. BMC Pulm Med. 2018;18(1):9.
   PubMedGoogle Scholar
• Hoyer N, Prior TS, Bendstrup E, et al. Risk factors for diagnostic delay in idiopathic pulmonary fibrosis. Respir Res. 2019;20(1):103.
   PubMed Web of Science ®Google Scholar
• Brereton CJ, Wallis T, Casey M, et al. Time taken from primary care referral to a specialist centre diagnosis of idiopathic pulmonary fibrosis: an opportunity to improve patient outcomes? ERJ Open Res. 2020;6(2):00120-2020.
   PubMedGoogle Scholar
• Hewson T, McKeever TM, Gibson JE, et al. Timing of onset of symptoms in people with idiopathic pulmonary fibrosis. Thorax. 2018;73(7):683–685.
   Web of Science ®Google Scholar
• Idiopathic Pulmonary Fibrosis Clinical Research Network; Raghu G, Anstrom KJ, King TE, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–1977.
   PubMed Web of Science ®Google Scholar
• Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ. 2016;352:h6819.
   PubMed Web of Science ®Google Scholar
• Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest. 2013;143(3):814–824.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Izawa M, Okada Y. Current trends in health insurance systems: OECD countries vs. Japan. Neurol Med Chir. 2015;55(4):267–275.
   Web of Science ®Google Scholar
• Richeldi L, Varone F, Bergna M, et al. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. Eur Respir Rev. 2018;27(150):180074.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718–1727.
   PubMed Web of Science ®Google Scholar
• Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8(2):147–157.
   PubMed Web of Science ®Google Scholar
• George PM, Spagnolo P, Kreuter M, et al. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med. 2020;8(9):925–934.
   PubMed Web of Science ®Google Scholar
• Wijsenbeek M, Kreuter M, Olson A, et al. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin. 2019;35(11):2015–2024.
   PubMed Web of Science ®Google Scholar
• Harari S. Beyond idiopathic pulmonary fibrosis: the world of progressive-fibrosing interstitial lung disease. Eur Respir Rev. 2018;27(150):180110.
   PubMed Web of Science ®Google Scholar
• Behr J, Neuser P, Prasse A, et al. Exploring efficacy and safety of oral pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) – a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. BMC Pulm Med. 2017;17(1):122.
   PubMedGoogle Scholar
• Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Urbania TH, Richeldi L, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J. 2013;42(3):750–757.
   PubMed Web of Science ®Google Scholar
• Fujisawa T, Mori K, Mikamo M, et al. Nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion. Eur Respir J. 2019;53(5):1802243.
   PubMed Web of Science ®Google Scholar
• Guler SA, Ellison K, Algamdi M, et al. Heterogeneity in unclassifiable interstitial lung disease. A systematic review and meta-analysis. Ann Am Thorac Soc. 2018;15(7):854–863.
   PubMed Web of Science ®Google Scholar
• Fisher JH, Kolb M, Algamdi M, et al. Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis. BMC Pulm Med. 2019;19(1):223.
   PubMed Web of Science ®Google Scholar
• Hyldgaard C, Bendstrup E, Wells AU, et al. Unclassifiable interstitial lung diseases: clinical characteristics and survival. Respirology. 2017;22(3):494–500.
   PubMed Web of Science ®Google Scholar
• Troy L, Glaspole I, Goh N, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J. 2014;43(5):1529–1530.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Kaner RJ, Guiot J, et al. Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype. Chest. 2020;158(2):646–659.
   PubMed Web of Science ®Google Scholar
• Organisation for Economic Cooperation and Development (OECD). Health at a glance. 2019; [cited 2020 Sep 8]. Available from: https://doi.org/10.1787/4dd50c09-en.
   Google Scholar
• Takada K, Katada Y, Ito S, et al. Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: a single-arm clinical trial. Rheumatology. 2020;59(5):1084–1093.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655–2666.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708–719.
   PubMed Web of Science ®Google Scholar
• Swigris JJ, Brown KK, Abdulqawi R, et al. Patients’ perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180075.
   PubMed Web of Science ®Google Scholar
• Holtze C, Flaherty K, Kreuter M, et al. Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180078.
   PubMed Web of Science ®Google Scholar
• Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–e68.
   PubMed Web of Science ®Google Scholar
• Chung JH, Goldin JG. Interpretation of HRCT scans in the diagnosis of IPF: improving communication between pulmonologists and radiologists. Lung. 2018;196(5):561–567.
   PubMed Web of Science ®Google Scholar
• Jo HE, Glaspole IN, Levin KC, et al. Clinical impact of the interstitial lung disease multidisciplinary service. Respirology. 2016;21(8):1438–1444.
   PubMed Web of Science ®Google Scholar
• Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518–2528.
   PubMed Web of Science ®Google Scholar